434 filings
Page 2 of 22
8-K
fb7eo dad5n5zem
23 Oct 14
Other Events
12:00am
8-K
vbbpx1dndv8ikf
17 Oct 14
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014 Annual Scientific Meeting
12:00am
8-K
9ae kjbqz43qyly
8 Oct 14
FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis
12:00am
8-K
ea1zocinsnj4 1kfeg
6 Oct 14
Salix Pharmaceuticals and Cosmo Technologies Announce Termination of
12:00am
8-K
fktg189 wngazi
30 Sep 14
FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain
12:00am
8-K
dv6zjtn pl
22 Sep 14
Results of XIFAXAN® 550mg TARGET 3 Study Selected by American
12:00am
8-K
flx41ru3appuw zi
18 Sep 14
Salix Secures Additional Intellectual Property
12:00am
8-K
tp16dvfadfzcv
16 Sep 14
UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
12:00am
8-K
k469no1ba waeudjpm2
2 Sep 14
Salix Submits Response to XIFAXAN® 550mg Complete
12:00am
8-K
ygkafglcs1mj
19 Aug 14
Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
12:00am
8-K
dlm1pqk4d7k uubw83r
12 Aug 14
Other Events
12:00am
8-K
n36rx
7 Aug 14
Salix Pharmaceuticals Reports 2Q2014 Results
12:00am
8-K
1jjrvpf
24 Jul 14
Conference Call and Webcast
12:00am
8-K
nqqjt hpnnbh
17 Jul 14
Other Events
12:00am
8-K/A
n7n4d
16 Jul 14
Other Events
12:00am
8-K
hfp5jcwzxbonz0
15 Jul 14
Other Events
12:00am
8-K
n2p5t ki5ps4q6czp
9 Jul 14
Entry into a Material Definitive Agreement
12:00am
8-K
8y32vx1o 4g0j
2 Jul 14
Other Events
12:00am
8-K
7fksdogq
26 Jun 14
Other Events
12:00am
8-K
9nb5i16ayz pvpaby9
17 Jun 14
Departure of Directors or Certain Officers
12:00am